Janus kinase (JAK) inhibitor-induced acne in inflammatory bowel disease - an international, multicenter, retrospective cohort study.

Date publication

juin 2025

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Honap S, Temido MJ, Shakweh E, Badrulhisham F, Shields N, Mehta S, McBride J, Uzzan M, Lukáš M, Fumery M, Nogami A, Kobayashi T, Nancey S, Neves JC, Mendes JM, Wegener BA, Bergereau E, Fernandes R, Kuriakose Kuzhiyanjal AJ, Vieujean S, Spencer A, Baillie S, Estevinho MM, Simão I, O'Neill C, Gututui M, Thompson E, Jama A, Chai N, Pavlidis P, D'Amico F, Limdi J, Magro F, Sebastian S, Digby-Bell J, Parkes GC, Din S, Hart A, Peyrin-Biroulet L,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40505791

Résumé

JAK inhibitor-associated acne is a common but poorly understood adverse event. This study aimed to investigate the epidemiology, clinical characteristics, and treatment outcomes of this condition in patients with inflammatory bowel disease (IBD).

Mots clés

Janus kinase inhibitors, acne, adverse event, filgotinib, tofacitinib, upadacitinib

Référence

Clin Gastroenterol Hepatol. 2025 06 10;: